Moreover, given the high plasticity of AML cells that enables them to adapt their metabolism and ensure their survival during chemotherapy38, targeting HSF1, either alone or in combination with conventional agents such as Ara-C could present additional options to target these transient leukemic-regenerating cells8. The gene discussed is HSF1; the disease is acute myeloid leukemia.